Advertisement

Langenbeck's Archives of Surgery

, Volume 404, Issue 3, pp 309–325 | Cite as

New approaches for the detection of invasive fungal diseases in patients following liver transplantation—results of an observational clinical pilot study

  • Sebastian O. Decker
  • Albert Krüger
  • Henryk Wilk
  • Silke Grumaz
  • Yevhen Vainshtein
  • Felix C. F. Schmitt
  • Florian Uhle
  • Thomas Bruckner
  • Stefan Zimmermann
  • Arianeb Mehrabi
  • Markus Mieth
  • Karl Heinz Weiss
  • Markus A. Weigand
  • Stefan Hofer
  • Kai Sohn
  • Thorsten BrennerEmail author
Original Article
  • 110 Downloads

Abstract

Purpose

Despite antifungal prophylaxis following liver transplantation (LTX), patients are at risk for the development of subsequent opportunistic infections, such as an invasive fungal disease (IFD). However, culture-based diagnostic procedures are associated with relevant weaknesses.

Methods

Culture and next-generation sequencing (NGS)-based fungal findings as well as corresponding plasma levels of ß-D-glucan (BDG), galactomannan (GM), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL)-2, -4, -6, -10, -17A and mid-regional proadrenomedullin (MR-proADM) were evaluated in 93 patients at 6 consecutive time points within 28 days following LTX.

Results

A NGS-based diagnostic approach was shown to be suitable for the early identification of fungal pathogens in patients following LTX. Moreover, MR-proADM and IL-17A in plasma proved suitable for the identification of patients with an IFD.

Conclusion

Plasma measurements of MR-proADM and IL-17A as well as a NGS-based diagnostic approach were shown to be attractive methodologies to attenuate the weaknesses of routinely used culture-based diagnostic procedures for the determination of an IFD in patients following LTX. However, an additional confirmation within a larger multicenter trial needs to be recommended.

Trial registration

German Clinical Trials Register: DRKS00005480.

Keywords

Candida spp. Aspergillus spp. Next-generation sequencing Interleukin-17A ß-D-glucan Mid-regional proadrenomedullin 

Notes

Acknowledgements

We would like to thank Ute Krauser and Karolina Glanz for their excellent technical assistance.

Authors’ contributions

SOD conceived the study, participated in its design and coordination, and helped in drafting the article. Furthermore, he performed data acquisition, carried out the measurements in the laboratory, and prepared the tables and figures. AK and HW performed data acquisition and were involved in critical revision of the article. FU, FCFS, AM, MM, KHW, MAW, and SH participated in the design of the study and were involved in revising the article. TBru participated in the design of the study and performed the statistical analysis. SZ performed all microbiological analyses and was involved in critical revision of the article. SG, YV, and KS were responsible for NGS-based diagnostics and revised the article critically. TBre conceived the study, participated in its design and coordination, and drafted the article. All authors read and approved the final manuscript.

Funding

The study was conducted with the financial support of the Department of Anesthesiology (Heidelberg University Hospital, Germany) and Fraunhofer IGB (Stuttgart, Germany). Furthermore, this study received financial grants from the B. Braun Foundation, Melsungen, as well as the Heidelberg Foundation of Surgery, and was supported by the European Union grant Fungitect. MR-proADM measurements were carried out by BRAHMS GmbH.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

423_2019_1769_MOESM1_ESM.pdf (893 kb)
ESM 1 (PDF 892 kb)

References

  1. 1.
    Trunecka P (2013) Immunosuppression after liver transplant, now and in future. Vnitr Lek 59(8):671–677Google Scholar
  2. 2.
    Reed A, Herndon JB, Ersoz N, Fujikawa T, Schain D, Lipori P, Hemming A, Li Q, Shenkman E, Vogel B (2007) Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 13(12):1743–1750.  https://doi.org/10.1002/lt.21331 Google Scholar
  3. 3.
    Singh N (2003) Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin N Am 17(1):113–134 viii Google Scholar
  4. 4.
    Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, Pfaller M, Steinbach WJ, Webster KM, Marr KA (2010) Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 12(3):220–229.  https://doi.org/10.1111/j.1399-3062.2010.00492.x Google Scholar
  5. 5.
    Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50(8):1101–1111.  https://doi.org/10.1086/651262 Google Scholar
  6. 6.
    Andes DR, Safdar N, Baddley JW, Alexander B, Brumble L, Freifeld A, Hadley S, Herwaldt L, Kauffman C, Lyon GM, Morrison V, Patterson T, Perl T, Walker R, Hess T, Chiller T, Pappas PG, Investigators T (2016) The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 18(6):921–931.  https://doi.org/10.1111/tid.12613 Google Scholar
  7. 7.
    Shah T, Lai WK, Gow P, Leeming J, Mutimer D (2005) Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 7(3–4):126–132.  https://doi.org/10.1111/j.1399-3062.2005.00108.x Google Scholar
  8. 8.
    Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, Wagener MM, Kusne S, Singh N (2003) Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75(12):2023–2029.  https://doi.org/10.1097/01.TP.0000065178.93741.72 Google Scholar
  9. 9.
    Eschenauer GA, Kwak EJ, Humar A, Potoski BA, Clarke LG, Shields RK, Abdel-Massih R, Silveira FP, Vergidis P, Clancy CJ, Nguyen MH (2015) Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant 15(1):180–189.  https://doi.org/10.1111/ajt.12993 Google Scholar
  10. 10.
    Fortun J, Martin-Davila P, Moreno S, Barcena R, de Vicente E, Honrubia A, Garcia M, Nuno J, Candela A, Uriarte M, Pintado V (2003) Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 52(5):813–819.  https://doi.org/10.1093/jac/dkg450 Google Scholar
  11. 11.
    Nagao M, Fujimoto Y, Yamamoto M, Matsumura Y, Kaido T, Takakura S, Uemoto S, Ichiyama S (2016) Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive aspergillosis. J Infect Chemother 22(2):84–89.  https://doi.org/10.1016/j.jiac.2015.11.005 Google Scholar
  12. 12.
    Barchiesi F, Mazzocato S, Mazzanti S, Gesuita R, Skrami E, Fiorentini A, Singh N (2015) Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. Liver Transpl 21(2):204–212.  https://doi.org/10.1002/lt.24032 Google Scholar
  13. 13.
    Silveira FP, Kusne S, Practice ASTIDCo (2013) Candida infections in solid organ transplantation. Am J Transplant 13(Suppl 4):220–227.  https://doi.org/10.1111/ajt.12114 Google Scholar
  14. 14.
    Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56(9):1284–1292.  https://doi.org/10.1093/cid/cit006 Google Scholar
  15. 15.
    Vazquez JA, Miceli MH, Alangaden G (2013) Invasive fungal infections in transplant recipients. Ther Adv Infect Dis 1(3):85–105.  https://doi.org/10.1177/2049936113491936 Google Scholar
  16. 16.
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for R, Treatment of Cancer/Invasive Fungal Infections Cooperative G, National Institute of A, Infectious Diseases Mycoses Study Group Consensus G (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 46(12):1813–1821.  https://doi.org/10.1086/588660 Google Scholar
  17. 17.
    Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, Grecchi C, Rebuffi C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, Azoulay E, Blot SI, Cornely OA, Lass-Florl C, Koehler P, Cuenca-Estrella M, de Lange DW, De Rosa FG, De Waele JJ, Dimopoulos G, Garnacho-Montero J, Hoenigl M, Kanj SS, Maertens J, Martin-Loeches I, Munoz P, Kullberg BJ, Agvald-Ohman C, Poulakou G, Rello J, Sanguinetti M, Taccone FS, Timsit JF, Torres A, Vazquez JA, Calandra T, from the Study Group for Infections in Critically Ill P, the Fungal Infection Study Group of the European Society of Clinical M, Infectious D, European Society of Intensive Care M, European Confederation of Medical M, Mycoses Study Group E, Research C (2018, 2019) Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections definitions in ICU patients (FUNDICU) project. Mycoses.  https://doi.org/10.1111/myc.12869
  18. 18.
    Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):e1–e60.  https://doi.org/10.1093/cid/ciw326 Google Scholar
  19. 19.
    Singh N, Husain S, Practice ASTIDCo (2013) Aspergillosis in solid organ transplantation. Am J Transplant 13(Suppl 4):228–241.  https://doi.org/10.1111/ajt.12115 Google Scholar
  20. 20.
    Singh N, Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K, Busuttil RW, Wagener MM, Wheat LJ (2015) Performance characteristics of galactomannan and beta-d-glucan in high-risk liver transplant recipients. Transplantation 99(12):2543–2550.  https://doi.org/10.1097/TP.0000000000000763 Google Scholar
  21. 21.
    Leeflang MM, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Zhang M, Bossuyt PM, Vandenbroucke-Grauls CM (2015) Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 12:CD007394.  https://doi.org/10.1002/14651858.CD007394.pub2 Google Scholar
  22. 22.
    Pfeiffer CD, Fine JP, Safdar N (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42(10):1417–1427.  https://doi.org/10.1086/503427 Google Scholar
  23. 23.
    Ljungman P (2001) Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61(2):187–196Google Scholar
  24. 24.
    Slifkin M, Doron S, Snydman DR (2004) Viral prophylaxis in organ transplant patients. Drugs 64(24):2763–2792Google Scholar
  25. 25.
    Giannella M, Bartoletti M, Morelli M, Cristini F, Tedeschi S, Campoli C, Tumietto F, Bertuzzo V, Ercolani G, Faenza S, Pinna AD, Lewis RE, Viale P (2016) Antifungal prophylaxis in liver transplant recipients: one size does not fit all. Transpl Infect Dis 18(4):538–544.  https://doi.org/10.1111/tid.12560 Google Scholar
  26. 26.
    Fortun J, Muriel A, Martin-Davila P, Montejo M, Len O, Torre-Cisneros J, Carratala J, Munoz P, Farinas C, Moreno A, Fresco G, Goikoetxea J, Gavalda J, Pozo JC, Bodro M, Vena A, Casafont F, Cervera C, Silva JT, Aguado JM, Grupo de Estudio de Infeccion en Pacientes Trasplantados-Grupo de Estudio de Micologia M, Red Espanola de Investigacion en Patologia I (2016) Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: a propensity score analysis. Liver Transpl 22(4):427–435.  https://doi.org/10.1002/lt.24391 Google Scholar
  27. 27.
    Decker SO, Sigl A, Grumaz C, Stevens P, Vainshtein Y, Zimmermann S, Weigand MA, Hofer S, Sohn K, Brenner T (2017) Immune-response patterns and next generation sequencing diagnostics for the detection of mycoses in patients with septic shock—results of a combined clinical and experimental investigation. Int J Mol Sci 18(8).  https://doi.org/10.3390/ijms18081796
  28. 28.
    Hospital HU (2006) Heidelberger Manual der Lebertransplantation. (2.Auflage)Google Scholar
  29. 29.
    Grumaz S, Stevens P, Grumaz C, Decker SO, Weigand MA, Hofer S, Brenner T, von Haeseler A, Sohn K (2016) Next-generation sequencing diagnostics of bacteremia in septic patients. Genome Med 8(1):73.  https://doi.org/10.1186/s13073-016-0326-8 Google Scholar
  30. 30.
    Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner P, Parkhill J, Loman NJ, Walker AW (2014) Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol 12:87.  https://doi.org/10.1186/s12915-014-0087-z Google Scholar
  31. 31.
    Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K (2010) False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 42(6–7):461–468.  https://doi.org/10.3109/00365541003602064 Google Scholar
  32. 32.
    Metan G (2013) The interaction between piperacillin-tazobactam and Aspergillus galactomannan antigenemia assay: is the story over? Infection 41(1):293–294.  https://doi.org/10.1007/s15010-012-0327-5 Google Scholar
  33. 33.
    Morris PJ (2004) Transplantation—a medical miracle of the 20th century. N Engl J Med 351(26):2678–2680.  https://doi.org/10.1056/NEJMp048256 Google Scholar
  34. 34.
    Sayegh MH, Carpenter CB (2004) Transplantation 50 years later—progress, challenges, and promises. N Engl J Med 351(26):2761–2766.  https://doi.org/10.1056/NEJMon043418 Google Scholar
  35. 35.
    Li C, Wen TF, Mi K, Wang C, Yan LN, Li B (2012) Analysis of infections in the first 3-month after living donor liver transplantation. World J Gastroenterol 18(16):1975–1980.  https://doi.org/10.3748/wjg.v18.i16.1975 Google Scholar
  36. 36.
    Kaltenborn A, Hartmann C, Salinas R, Ramackers W, Kleine M, Vondran FW, Barthold M, Lehner F, Klempnauer J, Schrem H (2015) Risk factors for short- and long-term mortality in liver transplant recipients with MELD score >/= 30. Ann Transplant 20:59–69.  https://doi.org/10.12659/AOT.892322 Google Scholar
  37. 37.
    Sganga G, Bianco G, Frongillo F, Lirosi MC, Nure E, Agnes S (2014) Fungal infections after liver transplantation: incidence and outcome. Transplant Proc 46(7):2314–2318.  https://doi.org/10.1016/j.transproceed.2014.07.056 Google Scholar
  38. 38.
    Smoter P, Nyckowski P, Grat M, Patkowski W, Zieniewicz K, Wronka K, Hinderer B, Morawski M (2014) Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience. Transplant Proc 46(8):2786–2789.  https://doi.org/10.1016/j.transproceed.2014.09.044 Google Scholar
  39. 39.
    Kawagishi N, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fujimori K, Satomi S (2006) Risk factors and impact of beta-D glucan on invasive fungal infection for the living donor liver transplant recipients. Tohoku J Exp Med 209(3):207–215Google Scholar
  40. 40.
    Fortun J, Martin-Davila P, Moreno S, De Vicente E, Nuno J, Candelas A, Barcena R, Garcia M (2002) Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 8(11):1065–1070.  https://doi.org/10.1053/jlts.2002.36239 Google Scholar
  41. 41.
    Gladdy RA, Richardson SE, Davies HD, Superina RA (1999) Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 5(1):16–24Google Scholar
  42. 42.
    Nieto-Rodriguez JA, Kusne S, Manez R, Irish W, Linden P, Magnone M, Wing EJ, Fung JJ, Starzl TE (1996) Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 223(1):70–76Google Scholar
  43. 43.
    Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, Group EFIS (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37.  https://doi.org/10.1111/1469-0691.12039 Google Scholar
  44. 44.
    Avni T, Leibovici L, Paul M (2011) PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 49(2):665–670.  https://doi.org/10.1128/JCM.01602-10 Google Scholar
  45. 45.
    Cummings LA, Kurosawa K, Hoogestraat DR, SenGupta DJ, Candra F, Doyle M, Thielges S, Land TA, Rosenthal CA, Hoffman NG, Salipante SJ, Cookson BT (2016) Clinical next generation sequencing outperforms standard microbiological culture for characterizing polymicrobial samples. Clin Chem 62(11):1465–1473.  https://doi.org/10.1373/clinchem.2016.258806 Google Scholar
  46. 46.
    Long Y, Zhang Y, Gong Y, Sun R, Su L, Lin X, Shen A, Zhou J, Caiji Z, Wang X, Li D, Wu H, Tan H (2016) Diagnosis of sepsis with cell-free DNA by next-generation sequencing technology in ICU patients. Arch Med Res 47(5):365–371.  https://doi.org/10.1016/j.arcmed.2016.08.004 Google Scholar
  47. 47.
    Grumaz C, Kirstahler P, Sohn K (2017) The molecular blueprint of a fungus by next-generation sequencing (NGS). Methods Mol Biol 1508:361–383.  https://doi.org/10.1007/978-1-4939-6515-1_21 Google Scholar
  48. 48.
    Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10(5):882–885Google Scholar
  49. 49.
    Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR (2006) Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 50(10):3450–3453.  https://doi.org/10.1128/AAC.00658-06 Google Scholar
  50. 50.
    Prattes J, Schneditz D, Pruller F, Jaindl E, Sauseng N, Hoenigl M, Schilcher G, Krause R (2017) 1,3-ss-d-Glucan testing is highly specific in patients undergoing dialysis treatment. J Inf Secur 74(1):72–80.  https://doi.org/10.1016/j.jinf.2016.09.005 Google Scholar
  51. 51.
    Metan G, Koc AN, Kaynar LG, Atalay A, Ozturk A, Eser B, Cetin M (2013) What is the role of the (1-->3)-beta-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? Mycoses 56(1):34–38.  https://doi.org/10.1111/j.1439-0507.2012.02195.x Google Scholar
  52. 52.
    Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, Viscoli C (2012) Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 67(7):1746–1748.  https://doi.org/10.1093/jac/dks111 Google Scholar
  53. 53.
    Furfaro E, Mikulska M, Del Bono V, Guolo F, Minetto P, Gobbi M, Ghiso A, Bacigalupo A, Viscoli C (2014) Bloodstream infections are an improbable cause of positive serum (1,3)-beta-D-glucan in hematology patients. Clin Vaccine Immunol 21(9):1357–1359.  https://doi.org/10.1128/CVI.00214-14 Google Scholar
  54. 54.
    Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26(4):781–803 quiz 804-785Google Scholar
  55. 55.
    Zedek DC, Miller MB (2006) Use of galactomannan enzyme immunoassay for diagnosis of invasive aspergillosis in a tertiary-care center over a 12-month period. J Clin Microbiol 44(4):1601.  https://doi.org/10.1128/JCM.44.4.1601.2006 Google Scholar
  56. 56.
    Krause R, Zollner-Schwetz I, Salzer HJ, Valentin T, Rabensteiner J, Pruller F, Raggam R, Meinitzer A, Prattes J, Rinner B, Strohmaier H, Quehenberger F, Strunk D, Heidrich K, Buzina W, Hoenigl M (2015) Elevated levels of interleukin 17A and kynurenine in candidemic patients, compared with levels in noncandidemic patients in the intensive care unit and those in healthy controls. J Infect Dis 211(3):445–451.  https://doi.org/10.1093/infdis/jiu468 Google Scholar
  57. 57.
    Cheng SC, van de Veerdonk F, Smeekens S, Joosten LA, van der Meer JW, Kullberg BJ, Netea MG (2010) Candida albicans dampens host defense by downregulating IL-17 production. J Immunol 185(4):2450–2457.  https://doi.org/10.4049/jimmunol.1000756 Google Scholar
  58. 58.
    Kim N, Yoon YI, Yoo HJ, Tak E, Ahn CS, Song GW, Lee SG, Hwang S (2016) Combined detection of serum IL-10, IL-17, and CXCL10 predicts acute rejection following adult liver transplantation. Mol Cell 39(8):639–644.  https://doi.org/10.14348/molcells.2016.0130 Google Scholar
  59. 59.
    Hawkes JE, Yan BY, Chan TC, Krueger JG (2018) Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 201(6):1605–1613.  https://doi.org/10.4049/jimmunol.1800013 Google Scholar
  60. 60.
    Li Y, Wei C, Xu H, Jia J, Wei Z, Guo R, Jia Y, Wu Y, Li Y, Qi X, Li Z, Gao X (2018) The immunoregulation of Th17 in host against intracellular bacterial infection. Mediat Inflamm 2018(6587296):1–13.  https://doi.org/10.1155/2018/6587296 Google Scholar
  61. 61.
    Angeletti S, Battistoni F, Fioravanti M, Bernardini S, Dicuonzo G (2013) Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis. Clin Chem Lab Med 51(5):1059–1067.  https://doi.org/10.1515/cclm-2012-0595 Google Scholar
  62. 62.
    Miguel D, Prieto B, Alvarez FV (2013) Biological variation and prognosis usefulness of new biomarkers in liver transplantation. Clin Chem Lab Med 51(6):1241–1249.  https://doi.org/10.1515/cclm-2012-0713 Google Scholar
  63. 63.
    Fabrega E, Crespo J, Casafont F, de La Pena J, Garcia-Unzueta MT, Amado JA, Pons-Romero F (1999) Adrenomedullin in liver transplantation and its relationship with vascular complications. Liver Transpl Surg 5(6):485–490Google Scholar
  64. 64.
    Geny B, Ellero B, Charloux A, Brandenberger G, Doutreleau S, Piquard F (2003) Circulating adrenomedullin is increased in relation with increased creatinine and atrial natriuretic peptide in liver-transplant recipients. Regul Pept 114(1):61–66Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Sebastian O. Decker
    • 1
  • Albert Krüger
    • 1
  • Henryk Wilk
    • 1
  • Silke Grumaz
    • 2
  • Yevhen Vainshtein
    • 2
  • Felix C. F. Schmitt
    • 1
  • Florian Uhle
    • 1
  • Thomas Bruckner
    • 3
  • Stefan Zimmermann
    • 4
  • Arianeb Mehrabi
    • 5
  • Markus Mieth
    • 5
  • Karl Heinz Weiss
    • 6
  • Markus A. Weigand
    • 1
  • Stefan Hofer
    • 7
  • Kai Sohn
    • 2
  • Thorsten Brenner
    • 1
    Email author
  1. 1.Department of AnesthesiologyHeidelberg University HospitalHeidelbergGermany
  2. 2.Fraunhofer IGBStuttgartGermany
  3. 3.Institute of Medical Biometry and InformaticsUniversity of HeidelbergHeidelbergGermany
  4. 4.Department of Infectious Diseases, Medical Microbiology and HygieneHeidelberg University HospitalHeidelbergGermany
  5. 5.Department of General, Visceral and Transplant SurgeryHeidelberg University HospitalHeidelbergGermany
  6. 6.Department of Internal Medicine IVHeidelberg University HospitalHeidelbergGermany
  7. 7.Department of AnesthesiologyWestpfalzklinikumKaiserslauternGermany

Personalised recommendations